Genetic Analysis
0.69 NOK
+4.55 %
Less than 1K followers
GEAN
Spotlight Stock Market
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Genetic Analysis
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 6.8 | 11.2 | 14.2 | 15.9 | 16.7 |
| growth-% | 64.1 % | 26.8 % | 12.3 % | 5.2 % | |
| EBITDA | -24.3 | 53.8 | -18.2 | -9.5 | -6.1 |
| EBIT | -28.9 | -28.2 | -23.8 | -14.2 | -11.3 |
| Profit before taxes | -29.0 | -28.3 | -23.8 | -14.8 | -11.4 |
| Net income | -29.0 | -28.3 | -23.8 | -14.8 | -11.4 |
| EPS | -1.16 | -1.13 | -0.62 | -0.34 | -0.18 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| EBITDA-% | -357.9 % | 481.8 % | -128.9 % | -60.0 % | -36.4 % |
| EBIT-% | -424.6 % | -252.5 % | -168.3 % | -89.5 % | -67.4 % |
| ROE | -40.2 % | -64.0 % | -74.5 % | -65.7 % | -42.1 % |
| ROI | -34.7 % | -43.9 % | -44.5 % | -34.9 % | -21.8 % |